Clinical Trials Logo

Type 2 Diabetes clinical trials

View clinical trials related to Type 2 Diabetes.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06462170 Not yet recruiting - Type 2 Diabetes Clinical Trials

Pancreatic Insulin Production Capacity (PIPC) - a Feasibility Study

PIPC
Start date: June 17, 2024
Phase: N/A
Study type: Interventional

The standard treatment for Type 2 diabetes involves management of the disease based on average of blood glucose control over the past few months. In this study, the investigators test for the participants' ability to produce insulin, which is the hormone that the body makes to control blood sugar levels. The body produces insulin in response to eating. The participants will drink a meal replacement shake, and then test the blood for levels of insulin produced over 2 hours. With blood tests taken five times over two hours, the investigators will measure the blood glucose (sugar), and insulin levels. This study will assess the differences in insulin produced in the participants and try to understand the reasons for these differences.

NCT ID: NCT06457984 Not yet recruiting - Type 2 Diabetes Clinical Trials

Effects of Selenium Towards Type 2 Diabetes

Start date: June 15, 2024
Phase: N/A
Study type: Interventional

According to the prevalence of non-communicable chronic diseases and aging population characteristics, this study is exploring the coexist effects combined with various dimensions: nutritional functions, metabolic homeostasis, inflammation and immunity by the selenium supplementation among type 2 diabetes, which based on insulin resistance, beta-cell function disorders, and body metabolic homeostasis disorders of the mechanism of type 2 diabetes by lifecycle so that could provide with a totally new and safe nutritional method for type 2 diabetes prevention and diagnosis.

NCT ID: NCT06457802 Not yet recruiting - Type 2 Diabetes Clinical Trials

Sit Less Program for Patients With Type 2 Diabetes

Start date: June 2024
Phase: N/A
Study type: Interventional

This randomized controlled trial aims to evaluate an 8-week intervention designed to reduce sedentary behavior (SB) in patients with type 2 diabetes (T2D) using wearable technology. The intervention involves the use of Fitbit devices to prompt standing/walking breaks, a smart water bottle to encourage hydration-related movement, and tailored text messages for behavior reinforcement. Participants will be assessed at baseline and post-intervention for changes in SB, light physical activity, cardiometabolic markers, and patient-centered outcomes. The study seeks to determine the intervention's acceptability and preliminary efficacy in reducing SB and improving health outcomes in T2D patients.

NCT ID: NCT06457139 Not yet recruiting - Type 2 Diabetes Clinical Trials

Preventing T2DM After GDM With Immediate Postpartum Screening and Treatment

Start date: April 1, 2025
Phase: Phase 1
Study type: Interventional

The overall goal of this proposal is to create and test an implementation protocol for in-hospital immediate postpartum diabetes screening and subsequent treatment with metformin for postpartum patients with pregnancies affected by GDM.

NCT ID: NCT06448130 Not yet recruiting - Type 2 Diabetes Clinical Trials

Henagliflozin's Impact on Prediabetes Remission

Start date: June 2024
Phase: Phase 4
Study type: Interventional

This clinical trial evaluates the effectiveness of Henagliflozin combined with lifestyle interventions for managing patients with prediabetes. As global prediabetes rates rise, increasing the risk of diabetes and vascular issues, addressing treatment gaps is essential. Henagliflozin, a novel SGLT2 inhibitor developed in China, aims to improve glucose control and metabolic health when paired with lifestyle changes. The study's primary objectives include: assessing whether Henagliflozin can achieve normoglycemia in prediabetic patients after 6 months of treatment. The trial will compare three groups (Henagliflozin 5mg, 10mg, and a placebo), focusing on efficacy and safety. Participants, assigned randomly, will undergo a 6-month treatment phase and an 18-month follow-up. Regular health assessments will monitor glucose levels, metabolic health, and risks of major complications like cardiovascular events and microvascular diseases, with additional evaluations of C-peptide and insulin changes. Structured as a multicenter, randomized, double-blind, placebo-controlled study, it involves 984 prediabetic adults across 50 medical institutions in China. This comprehensive approach could redefine prediabetes management by integrating drug therapy with lifestyle modifications.

NCT ID: NCT06442150 Not yet recruiting - Type 2 Diabetes Clinical Trials

LCMD for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual Differences

LCMD
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Type 2 diabetes (T2DM) has become a major public health problem. Achieving remission (HbA1c<6.5% without glucose-lowering medications) has recently become a new treatment goal. Low-calorie diets effectively induce remission, but adverse effects like fatigue, appetite, and constipation hinder success. Integrating traditional Chinese medicine (TCM) herbs into a low-calorie diet may alleviate adverse effects and improve remission rates. This project investigates the efficacy of a Low-Calorie Medicine Diet (LCMD) in achieving T2DM remission among overweight/obese individuals through a randomized controlled trial. The investigators will explore individual differences in remission and elucidate the underlying biological mechanisms, focusing on the brain-gut-microbiota axis. By integrating nutrition and TCM dietetics, this project provides a novel, evidence-based approach to managing T2DM in Chinese populations.

NCT ID: NCT06440486 Not yet recruiting - Type 2 Diabetes Clinical Trials

Assessment of Probiotics on Inflammation and Metabolism in Type 2 Diabetes.

Start date: June 15, 2024
Phase: N/A
Study type: Interventional

This clinical study aims to explore the effects of probiotics on inflammatory and metabolic indicators in patients with type 2 diabetes. By assessing the potential of probiotics to modify these markers, the study seeks to identify an economical and effective strategy for the prevention and treatment of type 2 diabetes.

NCT ID: NCT06439056 Not yet recruiting - Type 2 Diabetes Clinical Trials

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D

Start date: June 2024
Phase: Phase 1
Study type: Interventional

The purpose with the study is to assess pharmacokinetics of NEX-22A in patients with type 2 diabetes.

NCT ID: NCT06438874 Not yet recruiting - Type 2 Diabetes Clinical Trials

Type 2 Diabetes Post Exercise Arterial Stiffness

Start date: July 2024
Phase: N/A
Study type: Interventional

The overall aim of this research proposal is to determine the impact of GLP1 agonists on post-exercise arterial stiffness. Therefore, the investigators will examine the cardiovascular responses to exercise in individuals with Type 2 Diabetes mellitus (T2DM) taking these medications during and following a graded maximal exercise test.

NCT ID: NCT06428968 Not yet recruiting - Type 2 Diabetes Clinical Trials

Investigating the Insulin Resistance in Individuals With Type 2 Diabetes

Start date: May 15, 2024
Phase: N/A
Study type: Interventional

Numerous studies have provided evidence of a correlation between Type 2 Diabetes Mellitus (T2DM) and cognitive dysfunction, specifically in the realms of complex attention, information processing, and executive function. These impairments have been observed in middle-aged and elderly individuals with T2DM, with longer diabetes duration, suboptimal glycemic control, and the presence of diabetic complications being contributing factors. Recent research in young adults and adolescents diagnosed with T2DM has revealed cognitive and brain structural alterations in this growing demographic, suggesting that early disease mechanisms, rather than solely vascular and age-related neurodegeneration, contribute to pathogenesis. However, there remains uncertainty regarding the interplay between central and peripheral insulin resistance and its impact on cognitive dysfunction in individuals with T2DM. This study aims to investigate central insulin resistance in T2DM, elucidating its association with peripheral insulin resistance and the effects on cognitive impairments.